ABSTRACT
A growing number and diversity of complex medicines is in development and reaching the market, with many of these medicines utilising innovative delivery technology to achieve appropriate biodistribution and exposure. Accurate assessment of biodistribution, cell penetration, internalised form, cargo release and efficacy are essential for the development of these medicines. Advanced imaging technologies, deploying different labelling techniques that allow the assessment of both carrier and cargo, are enabling in-depth analysis and providing a mechanistic understanding of each step in the drug delivery pathway. Translation across cell, tissue and whole-body settings using multiple imaging methods can provide decision-making information that is critical for clinical phase selection and for the development of complex medicines.
Subject(s)
Molecular Imaging , Pharmaceutical Preparations , Tissue DistributionABSTRACT
Most cancer patients receive chemotherapy at some stage of their treatment which makes improving the efficacy of cytotoxic drugs an ongoing and important goal. Despite large numbers of potent anti-cancer agents being developed, a major obstacle to clinical translation remains the inability to deliver therapeutic doses to a tumor without causing intolerable side effects. To address this problem, there has been intense interest in nanoformulations and targeted delivery to improve cancer outcomes. The aim of this work was to demonstrate how vascular endothelial growth factor receptor 2 (VEGFR2)-targeted, ultrasound-triggered delivery with therapeutic microbubbles (thMBs) could improve the therapeutic range of cytotoxic drugs. Methods: Using a microfluidic microbubble production platform, we generated thMBs comprising VEGFR2-targeted microbubbles with attached liposomal payloads for localised ultrasound-triggered delivery of irinotecan and SN38 in mouse models of colorectal cancer. Intravenous injection into tumor-bearing mice was used to examine targeting efficiency and tumor pharmacodynamics. High-frequency ultrasound and bioluminescent imaging were used to visualise microbubbles in real-time. Tandem mass spectrometry (LC-MS/MS) was used to quantitate intratumoral drug delivery and tissue biodistribution. Finally, 89Zr PET radiotracing was used to compare biodistribution and tumor accumulation of ultrasound-triggered SN38 thMBs with VEGFR2-targeted SN38 liposomes alone. Results: ThMBs specifically bound VEGFR2 in vitro and significantly improved tumor responses to low dose irinotecan and SN38 in human colorectal cancer xenografts. An ultrasound trigger was essential to achieve the selective effects of thMBs as without it, thMBs failed to extend intratumoral drug delivery or demonstrate enhanced tumor responses. Sensitive LC-MS/MS quantification of drugs and their metabolites demonstrated that thMBs extended drug exposure in tumors but limited exposure in healthy tissues, not exposed to ultrasound, by persistent encapsulation of drug prior to elimination. 89Zr PET radiotracing showed that the percentage injected dose in tumors achieved with thMBs was twice that of VEGFR2-targeted SN38 liposomes alone. Conclusions: thMBs provide a generic platform for the targeted, ultrasound-triggered delivery of cytotoxic drugs by enhancing tumor responses to low dose drug delivery via combined effects on circulation, tumor drug accumulation and exposure and altered metabolism in normal tissues.
Subject(s)
Antineoplastic Agents/administration & dosage , Colorectal Neoplasms/drug therapy , Drug Delivery Systems/methods , Microbubbles/therapeutic use , Ultrasonic Waves , Antineoplastic Agents/pharmacokinetics , Biological Availability , Cell Line, Tumor , Colorectal Neoplasms/diagnostic imaging , Colorectal Neoplasms/pathology , Combined Modality Therapy/methods , Female , Humans , Irinotecan , Microfluidic Analytical Techniques , Positron-Emission Tomography , Tissue Distribution/radiation effects , Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors , Vascular Endothelial Growth Factor Receptor-2/metabolism , Xenograft Model Antitumor AssaysABSTRACT
Organs-on-a-chip (OOAC) are research platforms containing cellular models designed to recapitulate relevant biological cues and, in some cases, enable communication between 'on-chip' connected organs. With enhanced physiological relevance, improvements in predictivity of the efficacy and toxicity of test compounds are anticipated. However, there are challenges to demonstrate the 'gain of confidence' of this technology for patient benefit. Translational challenges, the opportunities and deficiencies of the organ models, their intercommunication and the platform technology are all issues to be resolved. Sensitive, real-time detection technologies and data-rich readouts are needed to understand OOAC biology. Thus, the validation of normal and disease biology on chip, and modelling to translate these data to patients, will help position this technology in mainstream drug discovery.
Subject(s)
Drug Discovery , Lab-On-A-Chip Devices , Tissue Engineering , Animals , Humans , Models, Biological , Translational Research, BiomedicalABSTRACT
Open innovation in pharmaceutical R&D evolved from a triple helix of convergent paradigm shifts in academic, industrial and government research sectors. The birth of the biotechnology sector catalyzed shifts in location dynamics that led to the first wave of open innovation in pharmaceutical R&D between big pharma and startup companies. The National Institutes of Health (NIH) Roadmap was a crucial inflection point that set the stage for a new wave of open innovation models between pharmaceutical companies and universities that have the potential to transform the pharmaceutical R&D landscape. We highlight the attributes of leading protected open innovation models that foster the sharing of proprietary small molecule collections by lowering the risk of premature escape of intellectual property, particularly structure-activity data.
Subject(s)
Drug Discovery , Biomedical Research , Drug Industry , Humans , Inventions , National Institutes of Health (U.S.) , Prostaglandin-Endoperoxide Synthases , United StatesABSTRACT
USP7 (HAUSP) is a deubiquitinating enzyme, which plays a crucial role in regulating the levels of the p53 tumour suppressor protein, through its ability to prevent the proteasomal degradation of the Ubiquitin ligase for p53, Hdm2. Supporting evidence suggests that an inhibitor of USP7 would act to abrogate the action of Hdm2, and thereby elevate levels of the p53 protein, with associated therapeutic benefits in cancer and potentially other diseases. In this article, we describe the characterisation of differential enzyme activity of both the full length and putative catalytic domain of human USP7 expressed in both bacterial and insect cell expression systems. We also demonstrate the way in which variations in the reducing environment surrounding the enzyme can dramatically affect both the stability of the enzyme and the range of small molecules able to inhibit the catalytic activity of the enzyme. Furthermore, we describe the validation and use of this assay for a high-throughput screening approach, again highlighting the critical nature of the enzyme's environment. Taken together, these findings not only increase our understanding of the enzymatic activity of deubiquitinating enzymes, but also highlight several key considerations of importance in the development of therapeutic agents against this novel class of therapeutic targets.
Subject(s)
Enzyme Inhibitors/pharmacology , Ubiquitin Thiolesterase/antagonists & inhibitors , Ubiquitin Thiolesterase/metabolism , Ubiquitin/metabolism , Amino Acid Sequence , Animals , Biocatalysis/drug effects , Catalytic Domain/genetics , Cell Line , Coumarins/metabolism , Dithiothreitol/pharmacology , Dose-Response Relationship, Drug , Electrophoresis, Polyacrylamide Gel , Enzyme Stability , Glutathione/pharmacology , Humans , Kinetics , Luminescent Proteins/genetics , Luminescent Proteins/metabolism , Maleimides/pharmacology , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/metabolism , Spectrometry, Fluorescence , Spodoptera , Substrate Specificity , Temperature , Ubiquitin/genetics , Ubiquitin Thiolesterase/genetics , Ubiquitin-Specific Peptidase 7 , Ubiquitins/metabolismABSTRACT
The development of a novel series of imidazole pyrimidine amides as cyclin-dependent kinase (CDK) inhibitors is described. Optimisation of inhibitory potency against multiple CDK's (1, 2 and 9) resulted in imidazole pyrimidine amides with potent in vitro anti-proliferative effects against a range of cancer cell lines. Excellent physiochemical properties and large margins against inhibition of CYP isoforms and the hERG ion channel were achieved by modification of lipophilicity and amine basicity. A candidate with disease model activity in human cancer cell line xenografts and with suitable physiochemical and pharmacokinetic profiles for intravenous (i.v.) dosing was selected for further development as AZD5597.
Subject(s)
Amides/chemistry , Cyclin-Dependent Kinase Inhibitor Proteins/chemistry , Imidazoles/chemical synthesis , Protein Kinase Inhibitors/chemical synthesis , Pyrimidines/chemistry , Cell Line, Tumor , Chemistry, Physical/methods , Crystallography, X-Ray , Cyclin-Dependent Kinase Inhibitor Proteins/pharmacology , Drug Design , ERG1 Potassium Channel , Ether-A-Go-Go Potassium Channels/metabolism , Humans , Imidazoles/pharmacology , Infusions, Intravenous , Models, Chemical , Molecular Conformation , Neoplasm Transplantation , Protein Isoforms , Protein Kinase Inhibitors/pharmacology , Pyrimidines/chemical synthesis , Pyrimidines/pharmacologyABSTRACT
Neurons are a diverse cell type exhibiting hugely different morphologies and neurotransmitter specifications. Their distinctive phenotypes are established during differentiation from pluripotent precursor cells. The signalling pathways that specify the lineage down which neuronal precursor cells differentiate remain to be fully elucidated. Among the many signals that impinge on the differentiation of neuronal cells, cytosolic calcium (Ca2+) has an important role. However, little is known about the nature of the Ca2+ signals involved in fate choice in neuronal precursor cells, or their sources. In this study, we show that activation of either muscarinic or platelet-derived growth factor (PDGF) receptors induces a biphasic increase in cytosolic Ca2+ that consists of release from intracellular stores followed by sustained entry across the plasma membrane. For both agonists, the prolonged Ca2+ entry occurred via a store-operated pathway that was pharmacologically indistinguishable from Ca2+ entry initiated by thapsigargin. However, muscarinic receptor-activated Ca2+ entry was inhibited by siRNA-mediated knockdown of TRPC6, whereas Ca2+ entry evoked by PDGF was not. These data provide evidence for agonist-specific activation of molecularly distinct store-operated Ca2+ entry pathways, and raise the possibility of privileged communication between these Ca2+ entry pathways and downstream processes.
Subject(s)
Calcium Channels/drug effects , Methacholine Chloride/pharmacology , Muscarinic Agonists/pharmacology , Neurons/drug effects , Platelet-Derived Growth Factor/pharmacology , Calcium Channels/metabolism , Calcium Signaling/drug effects , Cells, Cultured , Humans , Immunoblotting , Neurons/cytology , Neurons/metabolism , Time FactorsABSTRACT
High-content screening (HCS), a process that combines fluorescence microscopic imaging and automated image analysis, has had a significant impact on drug discovery since its introduction in the mid 1990s. The application of HCS within pharmaceutical drug discovery has become widespread, notably within oncology drug discovery. The trends, challenges and considerations for HCS that affect the successful and pragmatic implementation of this process in drug discovery will be outlined.
Subject(s)
Antineoplastic Agents/pharmacology , Animals , Antineoplastic Agents/therapeutic use , Drug Design , Drug Evaluation, Preclinical , Humans , Neoplasms/drug therapy , Neoplasms/genetics , Neoplasms/pathology , PhenotypeABSTRACT
Neurons are a diverse cell type exhibiting hugely different morphologies and neurotransmitter specifications. Their distinctive phenotypes are established during differentiation from pluripotent precursor cells. The signalling pathways that specify the lineage down which neuronal precursor cells differentiate remain to be fully elucidated. Among the many signáis that impinge on the differentiation of neuronal cells, cytosolic calcium (Ca2+) has an important role. However, little is known about the nature of the Ca2+ signáis involved in fate choice in neuronal precursor cells, or their sources. In this study, we show that activation of either muscarinic or platelet-derived growth factor (PDGF) receptors induces a biphasic increase in cytosolic Ca2+ that consists of reléase from intracellular stores followed by sustained entry across the plasma membrane. For both agonists, the prolonged Ca2+ entry occurred via a store-operated pathway that was pharmacologically indistinguishable from Ca2+ entry initiated by thapsigargin. However, muscarinic receptor-activated Ca2+ entry was inhibited by siRNA-mediated knockdown of TRPC6, whereas Ca2+ entry evoked by PDGF was not. These data provide evidence for agonist-specific activation of molecularly distinct store-operated Ca2+ entry pathways, and raise the possibility of privileged communication between these Ca2+ entry pathways and downstream processes.
Subject(s)
Humans , Calcium Channels/drug effects , Methacholine Chloride/pharmacology , Muscarinic Agonists/pharmacology , Neurons/drug effects , Platelet-Derived Growth Factor/pharmacology , Cells, Cultured , Calcium Channels/metabolism , Calcium Signaling/drug effects , Immunoblotting , Neurons/cytology , Neurons/metabolism , Time FactorsABSTRACT
Robust and reliable methods for the manipulation of neural cell lines, by passaging, plating, dye labeling, imaging, fixation, and immunocytochemistry, are required to enable consistent, reproducible screens to be performed. We describe herein procedures and processes we have established to maximize the level of consistency of cell plating, fixation, and dye or antibody labeling, to ensure that assays which we are running on a routine basis remain consistent across long periods of time. These procedures involve a variety of fully or semiautomated steps, using high-quality commercially available liquid handling and dispensing technology.
Subject(s)
Tissue Array Analysis/methods , Autoanalysis/methods , Humans , Tissue FixationABSTRACT
High-content imaging platforms capable of studying kinetic responses at a single-cell level have elevated kinetic recording techniques from labor-intensive low-throughput experiments to potential high-throughput screening assays. We have applied this technology to the investigation of heterogeneous cell cultures derived from primary neural tissue. The neuronal cultures mature into a coupled network and display spontaneous oscillations in intracellular calcium, which can be modified by the addition of pharmacological agents. We have developed algorithms to perform Fourier analysis and quantify both the degree of synchronization and the effects of modulators on the oscillations. Functional and phenotypic experiments can be combined using this approach. We have used post-hoc immunolabeling to identify subpopulations of cells in cocultures and to dissect the calcium responses of these cells from the population response. The combination of these techniques represents a powerful tool for drug discovery.
Subject(s)
Calcium Signaling , Cell Culture Techniques/methods , Cells, Cultured/chemistry , Algorithms , Animals , Brain/embryology , Cerebral Cortex/metabolism , Chemistry, Pharmaceutical/methods , Drug Design , Fourier Analysis , Kinetics , Neurons/metabolism , Rats , Signal Transduction , Time FactorsABSTRACT
The prospect of manipulating endogenous neural stem cells to replace damaged tissue and correct functional deficits represents a novel mechanism for treating a variety of central nervous system disorders. Using human neural precursor cultures and a variety of assays for studying stem cell behavior we have screened two libraries of commercially available compounds using an endpoint high content screening assay. We then performed detailed follow-up mechanistic studies on confirmed hits using endpoint and kinetics assays to characterize and differentiate the mechanisms of action of these compounds. The screening cascade employed successfully identified a number of active compounds with differing mechanisms of action. This approach shows how hits from a phenotypic screen can be prioritized and characterized by high content screening to identify potentially novel mechanisms and druggable targets to take forward into more conventional high-throughput screening approaches.
Subject(s)
Biological Assay/methods , Neurons/cytology , Stem Cells/cytology , Animals , Calcium/metabolism , Cells, Cultured , Drug Evaluation, Preclinical , Female , Humans , Kinetics , Neurites/physiology , Neurites/ultrastructure , Neurons/physiology , Rats , Signal Transduction/physiology , Stem Cells/physiologySubject(s)
Biosensing Techniques/methods , Drug Design , Drug Evaluation, Preclinical/methods , Signal Transduction , Biosensing Techniques/instrumentation , Calcium/metabolism , Drug Evaluation, Preclinical/instrumentation , Electrophysiology/methods , Fluorometry/instrumentation , Fluorometry/methods , Humans , Intracellular Signaling Peptides and Proteins/physiology , Kinetics , MaleABSTRACT
Screening of the Merck compound collection identified 6 as an unusually simple, low molecular weight hit with moderate affinity for GABAA receptors. The structural novelty of 6, compared to our advanced series of GABAA alpha5 inverse agonists, made it an attractive molecule for further exploration. This paper will describe the evolution of 6 into a new series of ligands with nanomolar affinity and functional selectivity for GABAA alpha5 receptor subtypes.
Subject(s)
Pyridazines/chemical synthesis , Receptors, GABA-A/drug effects , Animals , Cell Line , Humans , In Vitro Techniques , Ligands , Male , Mice , Microsomes, Liver/drug effects , Microsomes, Liver/metabolism , Patch-Clamp Techniques , Protein Subunits/physiology , Pyridazines/pharmacokinetics , Pyridazines/pharmacology , Radioligand Assay , Rats , Rats, Sprague-Dawley , Receptors, GABA-A/physiology , Recombinant Proteins/metabolism , Structure-Activity RelationshipABSTRACT
Invertebrate glutamate-gated chloride channels (GluCls) are important targets for anthelmintics and insecticides such as ivermectin. To facilitate screening for novel GluCl modulators, the Caenorhabditis elegans GluCl alpha2beta channel was chosen as a surrogate for parasite channels not yet cloned, and an inducible stable human embryonic kidney cell line was generated. Functional expression of the alpha2 and beta subunits was confirmed by whole-cell voltage clamp assays. Using this cell line, a high-throughput assay was developed that detects membrane potential changes associated with the activation of GluCls. In this assay, membrane depolarization was quantified via changes in fluorescence resonance energy transfer between two membrane-associated dyes. Robust and reproducible signals were detected in response to addition of glutamate or ivermectin. This assay was used for the screening of over 180,000 samples from natural and synthetic sources.
Subject(s)
Biological Assay/methods , Chloride Channels/drug effects , Chloride Channels/physiology , Glutamic Acid/pharmacology , Ion Channel Gating/physiology , Kidney/physiology , Patch-Clamp Techniques/methods , Spectrometry, Fluorescence/methods , Animals , Caenorhabditis elegans , Cells, Cultured , Dose-Response Relationship, Drug , Ion Channel Gating/drug effects , Kidney/drug effects , Recombinant Proteins/metabolism , Robotics/methodsABSTRACT
A great deal of information can be gained from kinetic fluorescence-based measurement of cellular responses; however, until recently the use of such approaches has been limited by the manual nature of the instrumentation available. Higher-throughput kinetic studies of signaling pathways are greatly facilitated by new confocal, liquid handling-enabled, high content screening (HCS) platforms. In the present work, we have implemented one such instrument, the BD(TM) Pathway HT bioimager (BD Biosciences, Rockville, MD), for studying regulation of neuronal signaling pathways. We have established a neuronal calcium oscillation model, whereby rate of oscillation, amplitude of oscillation, and level of synchronicity across the culture can be measured. We have implemented membrane potential measurement using fluorescence resonance energy transfer-based dyes, for single cell characterization on this platform, showing the benefits of a truly flexible excitation and recording system; this dye combination cannot be readily implemented on all HCS platforms because of constraints of excitation wavelengths. We have validated long-term intracellular calcium imaging experiments, using innovative dyes and BD Pathway HT's spinning disk-based confocal excitation. To maximize both throughput and reproducibility, walk-away automation integration of this bioimaging technology has been implemented, producing an affordable, compact platform for fully automated kinetic HCS.
Subject(s)
Calcium Signaling , Drug Evaluation, Preclinical/methods , Neurons/physiology , Amyloid beta-Protein Precursor/genetics , Amyloid beta-Protein Precursor/metabolism , Animals , Automation , Bicuculline/pharmacology , Cells, Cultured , Cerebral Cortex , Drug Evaluation, Preclinical/instrumentation , Embryo, Mammalian , Fluorescent Dyes , GABA Antagonists/pharmacology , Humans , Membrane Potentials , Mice , Mice, Transgenic , Neurons/drug effects , Receptors, N-Methyl-D-Aspartate/agonists , Reproducibility of Results , Valine/analogs & derivatives , Valine/pharmacologyABSTRACT
Neurosteroids have been shown to mediate some of their physiological effects via a modulatory site on type A inhibitory gamma-aminobutyric acid (GABAA) receptors. In particular, recent evidence has implicated selective potentiation of the delta subunit of GABAA receptors as an important mediator of in vitro and in vivo neurosteroid activity. However, this has been demonstrated for only a very small number of steroids, so both the generality of this finding, and the structural features of steroids which mediate functional delta-selectivity, are unclear. We have used a potentiometric assay based on fluorescence resonance energy transfer to measure GABA-activated responses in L(tk-) cells stably transfected with human GABAA receptor alpha4beta3delta and alpha4beta3gamma2 receptor subtypes. A set of 28 steroids were evaluated on these subtypes to characterise their functional potency and efficacy in modulating GABA responses. For most compounds there was a clear separation of their efficacy profiles between the receptor subtypes, with a substantially larger maximal response at the alpha4beta3delta receptor. 5beta-Pregnan-3beta-ol-20-one, 5beta-pregnane-3alpha,20beta-diol and 5beta-pregnane-3alpha,17alpha-diol-11,20-dione showed particularly high efficacy for alpha4beta3delta. No compounds were identified that simply inhibited responses at delta-containing receptors. However, 5beta-pregnane-3alpha,17alpha,20beta-triol, prednisolone 21-acetate, 4-pregnene-17alpha,20alpha-diol-3-one-20-acetate, 4-pregnen-20alpha-ol-3-one, and 5beta-pregnane-3alpha,17alpha,21-triol-20-one inhibited, though did not abolish, GABA responses at the alpha4beta3gamma2 subtype, while evoking modest-amplitude potentiation of alpha4beta3delta responses. Molecular modelling on this compound series using principal components analysis indicates that several structural features of steroids underlie their relative functional selectivity for potentiation of delta-containing GABAA receptors.